On June 15, 2023, Neuvivo, a late-clinical stage biopharmaceutical company developing a new treatment for ALS, announced that it has closed an $11 million round of financing led by PrimeStreet Capital. Wilson Sonsini Goodrich & Rosati advised Neuvivo on the transaction.

The funding will be used for the continued development of NP001, a patented macrophage-targeted technology, for the treatment of ALS. NP001 has shown promise to be effective in a large subset of people living with ALS, coupled with an excellent safety profile. Neuvivo is working to make this treatment broadly available to patients. 

The Wilson Sonsini team that advised Neuvivo included Mark Solakian, Priyanka Nawathe, and Sam Silverstein.

For more information, please see Neuvivo’s press release.